摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇 | 61337-89-1

中文名称
2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇
中文别名
1-(3-羟甲基吡啶-2-基)-4-甲基-2-苯基;1-(3-羟甲基吡啶-2)-2-苯基-4-甲基-哌嗪;米氮平杂质B;1-(3-羟基甲基吡啶基-2)-2-苯基-4-甲基哌嗪;米氮醇;1-(3-羟甲基吡啶-2-基)-4-甲基-2-苯基哌嗪;2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇1-(3-羟甲基吡啶-2)-2-苯基-4-甲基-哌嗪
英文名称
2-(4-methyl-2-phenyl-1-piperazinyl)-3-pyridinemethanol
英文别名
1-(3-hydroxymethylpyridin-2-yl)-2-phenyl-4-methylpiperazine;2-(4-methyl-2-phenylpiperazin-1-yl)-pyridine-3-methanol;1-(3-hydroxymethyl pyridyl-2)-2-phenyl-4-methylpiperazine;1-(3-Hydroxymethylpyridin-2-yl)-4-methyl-2-phenylpiperazine;[2-(4-methyl-2-phenylpiperazin-1-yl)pyridin-3-yl]methanol
2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇化学式
CAS
61337-89-1
化学式
C17H21N3O
mdl
MFCD08063948
分子量
283.373
InChiKey
PYZPABZGIRHQTA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    113-115°C
  • 沸点:
    478.8±45.0 °C(Predicted)
  • 密度:
    1.161±0.06 g/cm3(Predicted)
  • 溶解度:
    DMSO(少量)、甲醇(少量)
  • LogP:
    1.3 at 20℃
  • 表面张力:
    59.72N/m at 1g/L and 20℃

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.352
  • 拓扑面积:
    39.6
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    -20°C冰箱(在惰性气氛下)

SDS

SDS:6ceec47e4e76bce9ac196ae974c62e17
查看

制备方法与用途

用途:用作抗抑郁药米氮平中间体

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    米氮平酸 2-(4-methyl-2-phenyl-1-piperazinyl)-3-pyridinecarboxylic acid 61338-13-4 C17H19N3O2 297.357
    1-(3-氰基吡啶-2)-2-苯基-4-甲基哌嗪 1-(3-cyanopyridyl-2)-2-phenyl-4-methylpiperazine 61337-88-0 C17H18N4 278.357
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    米氮平 Mirtazapine 85650-52-8 C17H19N3 265.358
    米赛林 mianserin 24219-97-4 C18H20N2 264.37

反应信息

  • 作为反应物:
    描述:
    2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇硫酸 、 sodium hydroxide 作用下, 以 异丙醇 为溶剂, 以80%的产率得到米赛林
    参考文献:
    名称:
    PROCESS FOR PRODUCTION OF MIRTAZAPINE
    摘要:
    公开号:
    EP2135870B1
  • 作为产物:
    描述:
    2-氨基烟酸乙酯甲醇 、 sodium tetrahydroborate 、 sodium iodide 作用下, 以 四氢呋喃乙醇氯仿N,N-二甲基甲酰胺 为溶剂, 反应 19.75h, 生成 2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇
    参考文献:
    名称:
    一种米氮醇的合成方法
    摘要:
    本发明公开了一种米氮醇的合成方法,是将N‑(2‑氯乙基)‑N‑甲基‑α‑氯‑β‑苯乙胺溶解在非极性溶剂与水的混合溶液中得到溶液A,2‑氨基‑3‑羟甲基吡啶溶解在含少量低碳醇的非极性溶剂中得到溶液B,将溶液B滴加到溶液A中反应得到的中间体溶解在无水高沸点极性溶剂中,惰性气体保护下滴加到无机碘化物的无水高沸点极性溶剂中,反应得到米氮醇。本发明方法将合成米氮醇的步骤拆分成两步,特定的溶剂体系避免了中间体直接高温反应被氧化,提高了反应的稳定性和收率。
    公开号:
    CN104892608B
点击查看最新优质反应信息

文献信息

  • Tetracyclic compounds
    申请人:Akzona Incorporated
    公开号:US04062848A1
    公开(公告)日:1977-12-13
    The invention relates to compounds of the general formula I: ##STR1## or a salt thereof, in which A represents a pyridine ring or a halogen substituted pyridine ring, R.sub.1 represents hydrogen, alkyl (1-6 C), alkoxy (1-6 C), alkylthio (1-6 C), halogen, OH, SH or CF.sub.3 R.sub.2 represents hydrogen or a lower alkyl or aralkyl group and n and m may each be 1, 2 or 3 with the proviso that the sum of m and n must be 2, 3 or 4, having CNS activity, a pronounced antihistamine activity and little or no antiserotonin activity.
    该发明涉及一般式I的化合物:##STR1##或其盐,其中A代表吡啶环或卤代吡啶环,R.sub.1代表、烷基(1-6 C)、烷基(1-6 C)、烷基(1-6 C)、卤素、羟基、基或三甲基,R.sub.2代表或较低的烷基或芳基基团,n和m可以分别为1、2或3,但m和n的总和必须为2、3或4,具有中枢神经系统活性、显著的抗组胺活性和很少或没有抗5-羟色胺活性。
  • METHOD FOR THE PREPARATION OF AN ENANTIOMERICALLY PURE BENZAZEPINE
    申请人:Kemperman Gerardus Johannes
    公开号:US20080255349A1
    公开(公告)日:2008-10-16
    The invention relates to a method for the preparation of a cyclic compound according to formula III comprising reacting a compound according to Formula I and a compound according to formula II, wherein in Formula I, R 1 , R 2 , R 3 and R 4 may be hydrogen or substituent groups comprising one or more carbon atoms and/or hetero-atoms, wherein R 1 , R 2 , R 3 and R 4 can be combined in aromatic or aliphatic ring structures, —Y is a ring element comprising 1-3 substituted or unsubstituted carbon atoms and/or heteroatoms in the ring and —R 5 is hydrogen or a hydrocarbon substituent group comprising one or more carbon atoms and optionally one or more hetero atoms, and wherein in Formula II, Z 1 and Z 2 are, leaving groups, X is a reactive functional hydrocarbon group for subsequent ring closure, comprising one or more carbon atoms and a reactive functional group and having a chain of between 1 to 6 atoms between the carbon atom attached to the central carbon atom of formula II and the reactive functional group and R 8 is hydrogen or a hydrocarbon substituent different from X making the central carbon atom of formula II a chiral centre in Formula III and wherein reactive functional group X can be or can be extended to be compound of formula IV which can be ring closed to produce the polycyclic component of formula V. More in particular, the invention relates to the preparation of mirtazapine precursors and mirtazapine preferably having a substantial enantiomeric excess.
    该发明涉及一种制备按照公式III的环状化合物的方法,包括将按照公式I的化合物与按照公式II的化合物反应,其中在公式I中,R1、R2、R3和R4可以是或含有一个或多个原子和/或杂原子的取代基团,其中R1、R2、R3和R4可以结合在芳香族或脂肪族环结构中,-Y是一个环元素,包括环中的1-3个取代或未取代的原子和/或杂原子,-R5是或一个含有一个或多个原子和可能一个或多个杂原子的烃取代基团,而在公式II中,Z1和Z2是离去基团,X是一个反应性功能烃基,用于随后的环闭合,包括一个或多个原子和一个反应性功能基团,并且在公式II的中心原子上附着的原子与反应性功能基团之间有1到6个原子的链,R8是或与X不同的烃取代基团,使公式III中的中心原子成为手性中心,并且反应性功能基团X可以是或可以扩展为公式IV的化合物,可以环闭合以产生公式V的多环组分。更具体地,该发明涉及米氮平前体和米氮平的制备,最好具有显著的对映体过量。
  • METHOD FOR THE PREPARATION OF AN ENANTIOMER OF A TETRACYCLIC BENZAZEPINE
    申请人:Kemperman Gerardus Johannes
    公开号:US20080255348A1
    公开(公告)日:2008-10-16
    The present invention relates to a method for the preparation of mirtazapine and tetracyclic analogous compounds having substantial enantiomeric excess of the R or S form. The invention further relates to a novel intermediate and its use for the preparation of mirtazapine having a substantial enantiomeric excess of the R or S form. The method comprising the steps of a: providing a carboxylic acid compound according to Formula I having a substantial enantiomeric excess of the R or S form, b: converting the carboxylic acid group of compound I into a ketone group, producing a ketone compound of Formula II, c: optionally reducing ketone compound II with a mild reduction agent to form the intermediate hydroxy compound of Formula III and d: forming the mirtazapine of Formula IV by reduction of the ketone compound II or of the hydroxy compound III using a strong reduction agent.
    本发明涉及一种制备米氮平和具有R或S形式的显着对映体过量的四环类似化合物的方法。该发明进一步涉及一种新颖的中间体及其用于制备米氮平具有R或S形式显着对映体过量的用途。该方法包括以下步骤:a:提供符合式I的羧酸化合物,其具有显着的R或S形式对映体过量,b:将化合物I的羧基转化为基,生成符合式II的化合物,c:可选择地使用温和还原剂还原化合物II,形成符合式III的中间羟基化合物,d:通过使用强还原剂还原化合物II或羟基化合物III来形成符合式IV的米氮平
  • Synthesis of piperazine ring
    申请人:Teva Pharmaceuticals Industries, Ltd.
    公开号:US06339156B1
    公开(公告)日:2002-01-15
    A novel process for preparing a compound of the formula I: wherein R1 denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy or arylalkoxy; R2 denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy, arylalkoxy, tosyl, formyl, acetyl or amine; and R3 denotes substituted or unsubstituted alkyl, alkoxy, aryl, aryloxy or arylalkoxy is disclosed. These compounds are useful in the synthesis of the antidepressant mirtazapine and other tetracyclic compounds.
    本发明公开了一种制备式I化合物的新工艺:其中,R1表示取代或未取代的烷基、烷基、芳基、芳基或芳基烷基;R2表示取代或未取代的烷基、烷基、芳基、芳基、芳基烷基、对甲苯磺酰基、甲酰基或胺基;R3表示取代或未取代的烷基、烷基、芳基、芳基或芳基烷基。这些化合物在合成抗抑郁药米氮平和其他四环类化合物中很有用。
  • Novel method for the preparation of piperazine and its derivatives
    申请人:——
    公开号:US20020095038A1
    公开(公告)日:2002-07-18
    A novel method for the synthesis of piperazine and its derivatives of formula 1, 1 wherein R is selected from hydrogen, or a lower alkyl group having 1 to 6 carbon atoms or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; R 1 is selected from hydrogen, a methyl group, a phenyl group optionally substituted with an alkyl group having 1 to 6 carbon atoms, or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; and R 2 is selected from hydrogen, or a methyl group, or a fluoromethyl group; 2 comprising the steps: a. reacting an ester of formula 11 with substituted or unsubstituted ethylenediamine of formula 7 to give 3,4-dehydropiperazine-2-one and its derivatives of formula 12, wherein R, R 1 , R 2 are as defined above and R 6 is a C 1 to C 4 linear or branched alkyl group; and b. reacting the 3,4-dehydro-piperazine-2-one and its derivatives of formula 12 with a reducing agent to yield the piperazine and its derivatives of formula 1.
    一种合成1,1-哌嗪及其衍生物的新方法,其中R选择,或者具有1至6个原子的低级烷基基团或基烷基基团,其烷基具有1至4个原子; R1选择甲基基(可选地带有1至6个原子的烷基基团)或基烷基基团,其烷基具有1至4个原子; R2选择甲基甲基; 2包括以下步骤:a. 反应式11的与式7的取代或未取代的乙二胺反应,得到式12的3,4-去哌嗪-2-及其衍生物,其中R,R1,R2如上所定义,R6为C1至C4线性或支链烷基基团; b. 反应式12的3,4-去哌嗪-2-及其衍生物与还原剂反应,得到式1的哌嗪及其衍生物
查看更多